Your browser doesn't support javascript.
loading
CCL2 is transcriptionally controlled by the lysosomal protease cathepsin S in a CD74-dependent manner.
Wilkinson, Richard D A; Magorrian, Sinead M; Williams, Rich; Young, Andrew; Small, Donna M; Scott, Christopher J; Burden, Roberta E.
Afiliação
  • Wilkinson RD; Molecular Therapeutics, School of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, UK.
  • Magorrian SM; Molecular Therapeutics, School of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, UK.
  • Williams R; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, BT9 7BL, UK.
  • Young A; Molecular Therapeutics, School of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, UK.
  • Small DM; Molecular Therapeutics, School of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, UK.
  • Scott CJ; Molecular Therapeutics, School of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, UK.
  • Burden RE; Molecular Therapeutics, School of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, UK.
Oncotarget ; 6(30): 29725-39, 2015 Oct 06.
Article em En | MEDLINE | ID: mdl-26358505
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígenos de Diferenciação de Linfócitos B / Antígenos de Histocompatibilidade Classe II / Catepsinas / Ativação Transcricional / Quimiocina CCL2 Limite: Animals / Humans Idioma: En Revista: Oncotarget Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígenos de Diferenciação de Linfócitos B / Antígenos de Histocompatibilidade Classe II / Catepsinas / Ativação Transcricional / Quimiocina CCL2 Limite: Animals / Humans Idioma: En Revista: Oncotarget Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Reino Unido